448 related articles for article (PubMed ID: 27226264)
1. Hypothyroidism risk compared among nine common bipolar disorder therapies in a large US cohort.
Lambert CG; Mazurie AJ; Lauve NR; Hurwitz NG; Young SS; Obenchain RL; Hengartner NW; Perkins DJ; Tohen M; Kerner B
Bipolar Disord; 2016 May; 18(3):247-60. PubMed ID: 27226264
[TBL] [Abstract][Full Text] [Related]
2. [Antipsychotics in bipolar disorders].
Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
[TBL] [Abstract][Full Text] [Related]
3. Mood stabilizers and atypical antipsychotics: bimodal treatments for bipolar disorder.
Ketter TA; Nasrallah HA; Fagiolini A
Psychopharmacol Bull; 2006; 39(1):120-46. PubMed ID: 17065977
[TBL] [Abstract][Full Text] [Related]
4. Mortality risk and mood stabilizers in bipolar disorder: a propensity-score-weighted population-based cohort study in 2002-2018.
Chan JKN; Wong CSM; Fang CZ; Hung SC; Lo HKY; Chang WC
Epidemiol Psychiatr Sci; 2024 May; 33():e31. PubMed ID: 38779809
[TBL] [Abstract][Full Text] [Related]
5. [Guidelines for the prescription of mood stabilizers for adolescents: A literature review].
Munch G; Godart N
Encephale; 2017 Oct; 43(5):464-470. PubMed ID: 27871720
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials.
Smith LA; Cornelius V; Warnock A; Bell A; Young AH
Bipolar Disord; 2007 Jun; 9(4):394-412. PubMed ID: 17547586
[TBL] [Abstract][Full Text] [Related]
7. Treatments for late-life bipolar disorder.
Aziz R; Lorberg B; Tampi RR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):347-64. PubMed ID: 17296540
[TBL] [Abstract][Full Text] [Related]
8. Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.
Nasrallah HA; Brecher M; Paulsson B
Bipolar Disord; 2006 Oct; 8(5 Pt 1):467-74. PubMed ID: 17042884
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive comparison of monotherapies for psychiatric hospitalization risk in bipolar disorders.
Nestsiarovich A; Mazurie AJ; Hurwitz NG; Kerner B; Nelson SJ; Crisanti AS; Tohen M; Krall RL; Perkins DJ; Lambert CG
Bipolar Disord; 2018 Dec; 20(8):761-771. PubMed ID: 29920885
[TBL] [Abstract][Full Text] [Related]
10. Self-harm, Unintentional Injury, and Suicide in Bipolar Disorder During Maintenance Mood Stabilizer Treatment: A UK Population-Based Electronic Health Records Study.
Hayes JF; Pitman A; Marston L; Walters K; Geddes JR; King M; Osborn DP
JAMA Psychiatry; 2016 Jun; 73(6):630-7. PubMed ID: 27167638
[TBL] [Abstract][Full Text] [Related]
11. Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study.
Hayes JF; Marston L; Walters K; Geddes JR; King M; Osborn DP
PLoS Med; 2016 Aug; 13(8):e1002058. PubMed ID: 27483368
[TBL] [Abstract][Full Text] [Related]
12. Weight gain in bipolar disorder: pharmacological treatment as a contributing factor.
Torrent C; Amann B; Sánchez-Moreno J; Colom F; Reinares M; Comes M; Rosa AR; Scott J; Vieta E
Acta Psychiatr Scand; 2008 Jul; 118(1):4-18. PubMed ID: 18498432
[TBL] [Abstract][Full Text] [Related]
13. Quetiapine and classical mood stabilizers in the long-term treatment of Bipolar Disorder: a 4-year follow-up naturalistic study.
Altamura AC; Mundo E; Dell'Osso B; Tacchini G; Buoli M; Calabrese JR
J Affect Disord; 2008 Sep; 110(1-2):135-41. PubMed ID: 18329720
[TBL] [Abstract][Full Text] [Related]
14. Diabetes mellitus risk for 102 drugs and drug combinations used in patients with bipolar disorder.
Nestsiarovich A; Kerner B; Mazurie AJ; Cannon DC; Hurwitz NG; Zhu Y; Nelson SJ; Oprea TI; Crisanti AS; Tohen M; Perkins DJ; Lambert CG
Psychoneuroendocrinology; 2020 Feb; 112():104511. PubMed ID: 31744781
[TBL] [Abstract][Full Text] [Related]
15. Comparative neurocognitive effects of lithium and anticonvulsants in long-term stable bipolar patients.
Sabater A; García-Blanco AC; Verdet HM; Sierra P; Ribes J; Villar I; Lara MJ; Arnal P; Rojo L; Livianos L
J Affect Disord; 2016 Jan; 190():34-40. PubMed ID: 26480209
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of manic phases of bipolar disorder: critical synthesis of international guidelines].
Geoffroy PA; Bellivier F; Henry C
Encephale; 2014 Sep; 40(4):330-7. PubMed ID: 24513018
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy and tolerability of drug treatments for bipolar disorder.
Strakowski SM; DelBello MP; Adler CM
CNS Drugs; 2001; 15(9):701-18. PubMed ID: 11580309
[TBL] [Abstract][Full Text] [Related]
18. Evolving trends in the long-term treatment of bipolar disorder.
Vieta E; Rosa AR
World J Biol Psychiatry; 2007; 8(1):4-11. PubMed ID: 17366344
[TBL] [Abstract][Full Text] [Related]
19. Trends in pharmacotherapy in patients referred to a bipolar specialty clinic, 2000-2011.
Hooshmand F; Miller S; Dore J; Wang PW; Hill SJ; Portillo N; Ketter TA
J Affect Disord; 2014 Feb; 155():283-7. PubMed ID: 24314912
[TBL] [Abstract][Full Text] [Related]
20. Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics.
Selle V; Schalkwijk S; Vázquez GH; Baldessarini RJ
Pharmacopsychiatry; 2014 Mar; 47(2):43-52. PubMed ID: 24549862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
